Baxter Recalls Peritoneal Dialysis Solution Baxter announced positive results from a Phase 3 trial evaluating BAX 817 for the treatment of patients with hemophilia A or B who develop inhibitors.

Healthcare company Baxter International (NYSE:BAX) reported Q1 CY2026 results , with sales up 2.9% year on year to $2.70 ...

We recently published Massive Sell-Off: 10 Stocks in a Bloodbath. Baxter International Inc. (NYSE:BAX) is one of the worst-performing stocks on Thursday. Baxter International dropped its share prices ...

Members of Congress have traded $BAX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales. Here’s a breakdown of recent ...